Administrative Supplement to 1 UG3 NS106938-02: “NIBA-TBI: Neuro-Imaging and biofluid-based Biomarker Assessments as translational pathophysiological outcome measures in TBI

摘要/摘要（行政补充） 与神经创伤转化成果项目（TOPNT）（UG 3/UH 3）RFA的愿景一致， 我们组建了一个多学科团队，并提出评估两个互补的病理机制- 基于TBI的结果测量-（i）生物流体生物标志物评估，和（ii）MRI-神经成像生物标志物 考核这一行政补充文件的目的是促进跨地点协调， 在4个受资助的研究中心验证神经成像和基于生物流体的生物标志物方法。我们有 补充目标A1：开发和优化多参数MRI 完全满足联盟中所有实验室的需求并确定跨实验室测量的协议 MRI校准模型、健康对照大鼠和离体大鼠脑的重现性。补充 目的B1-使纯化的大鼠和/或小鼠和人GFAP及其钙蛋白酶和半胱天冬酶消化物 使用蛋白质印迹、ELISA和质谱法在两个UG 3 TOP-NT上进行不同的测量测定 生物标志物实验室（UCLA和UF）。补充目标B2-在UF和UCLA研究中心，处死动物 将用上述GFAP测定方法检查生物样品（对照，损伤的）。

Summary / Abstract (Administrative Supplement) Consistent with the vision of the Translational Outcomes Project in Neurotrauma (TOPNT) (UG3/UH3) RFA, we assembled a multidisciplinary team and proposed to evaluate two complementary pathological mechanism- based TBI outcome measures – (i) biofluid biomarker assessment, and (ii) MRI-neuroimaging biomarker assessment. The objective of this administrative supplement is to facilitate cross-site harmonization and validation of neuroimaging and biofluid-based biomarker methods across the 4 funded study centers. We have the following supplementary aims: Supplementary Aim A1: To develop and optimize a multiparametric MRI protocol that completely meets needs for all labs in the consortium and to determine cross-lab measurement reproducibility on MRI calibration phantoms, live healthy control rats, and ex vivo rat brains. Supplementary Aim B1- Subject purified rat, and/or mouse and human GFAP and their calpain and caspase-digest to different measurement assays using western blot, ELISA and mass spectrometry at the two UG3 TOP-NT biomarker lab (UCLA, and UF). Supplementary Aim B2- At both UF and UCLA sites, terminal animal biosamples (control, injured) will be examined with the above GFAP assay approaches.